Azilsartan medoxomil potassium (QR-01019K), an angiotensin II receptor antagonist, exhibits a potent and sustained antihypertensive effect, along with a more pronounced and enduring reduction in heart rate, and a high safety profile. It shows promise for investigation in the management of hypertension, chronic heart failure, and diabetic nephropathy[1].